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1. Introduction 
1.1 Definition 
Polycystic ovary syndrome (PCOS) is a remarkably common disorder of premenopausal 
women with a prevalence of 5-10%. Besides reproductive endocrine abnormalities, 
including amenorrhea or oligomenorrhea, hyperandrogenism and infertility, patients with 
PCOS often show an insulin resistance and beta-cell dysfunction (1). 
1.2 Diagnostic criteria 
The condition was described by Stein and Leventhal in 1935. There is a considerable 
controversy on the optimal criteria for PCOS. Although the NIH (National Institute of 
Health) criteria as hyperandrogenic anovulatory PCOS were proposed in 1992, these have 
now expanded to non NIH criteria including hyperandrogenic ovulatory to non-
hyperandrogenic anovulatory PCOS (2). After a meeting between ESHRE (European Society 
for Human Reproduction and Embryology) and ASRM (American Society for Reproductive 
Medicine) in Rotterdam in 2003, a new set of criteria for PCOS was proposed, commonly 
refered to as Rotterdam criteria: 1. irregular/no ovulations, 2. clinical/paraclinical 
hyperandrogenemia and 3. polycystic ovaries. Two out of the three criteria need to be 
fulfilled and other causes of hyperandrogenemia should by excluded. The Rotterdam 
criteria are curently debated because they introduced two new fenotypes (3). It is known 
that the metabolic disturbances of PCOS are more pronounced in hyperandrogen patients 
compared to patients with no hyperandrogenemia in genetic studies. In 2006 AES 
(Androgen Excess Society) published a position statement which suggested that androgen 
excess is the key component of PCOS related to clinical symptoms and long–term morbidity. 
According to AES, diagnostic criteria should be modified to include only those with 
hyperandrogenism and polycystic ovary or ovarian dysfunction (2). This definition 
excluded the phenotype subset of polycystic ovary and ovarian dysfunction without 
hyperandrogenism.  
NIH criteria covered first two phenotypes: A and B, Rotterdam criteria covered all four 
phenotypes (including non hyperandrogenic anovulatory polycystic ovary) and finally AES 
criteria excluded non-hyperandrogenic  phenotype Table 1 (2).  
These criteria recognize that PCOS is a functional disorder in which ovarian 
hyperandrogenism can occur in the presence or absence of ovarian morphologic changes. 
However, according to Rotterdam criteria or AES criteria, polycystic ovaries need not to be 
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present to make a diagnosis of PCOS and controversely their presence alone does not 
establish the diagnosis of PCOS (2).  
 
Features Phenotypes 
 A B C D E F G 
Hyperandrogenism (biochemical/clinical) + + + - + - - 
Oligo - or anovulation + + - + - - + 
Polycystic ovaries + - + + - + - 
NIH criteria √ √      
ESHRE/ASRM criteria √ √ √ √    
AES criteria √ √ √     
Table 1. Comparison of the different reproductive diagnostic criteria for PCOS resulting in 
potentially different phenotypes (2) 
1.3 Ethiopathogenesis 
Although exact pathogenic mechanisms of PCOS are still not completely rocognised, most 
of factors involved in the development of PCOS can be devided into following groups: 
• Aberration of gonadotropic secretion 
• Genetics 
• Environmental factors 
• Hyperinsulinemia and insulin resistance 
1.4 Aberration of gonadotropic secretion 
It is well known, that gonadotropin-releasing hormone (GnRH) pulse frequency is 
accelerated in PCOS. However, it is not clear whether this accelerated pulse frequency is 
primarily or secondarily to the relatively low levels of progesterone resulting in rare 
ovulatory events. Both situations lead to an increase luteinizing hormone (LH) levels 
resulting in increased ovarian androgen production (4). 
1.5 Genetics 
Lines of evidence suggest that PCOS is a heritable disorder. Various approaches have been 
undertaken to try to define a specific genetic etiology. While a number of candidate genes 
appear to make modest contributions to the clinical expression of PCOS, no single gene has 
been confidentaly identified to play a predominant role in the pathogenesis of PCOS.  
Family studies showed a PCOS prevalence of 25-50% in first degree relatives of patients 
with PCOS, suggesting a strong inheritance of PCOS. PCOS is a heterogenous disease and 
the genetic profile of different phenotypes may differ (5). In the study of Franks et al. 
authors compared metabolic and hormonal parametres of probands with PCOS and 
oligoamenorrhea with affected sisters with ultrasound findings of polycystic ovary. 
Although affected sisters had fewer symptoms that probands, serum testosterone, LH and 
insulin sensitivity index were similar in both groups. Affected sisters had also the higher 
frequency of oligomenorrhea, hirsutism and other hyperandrogenic symptoms. Thus 
authors demostrated a moderate to high heritability for all traits studied in affected pairs 
Figure 1, Figure 2 (6). 
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Fig. 1. Distribution of symptoms in probands with PCOS and affected sisters (6). 
 
 
 
 
 
Fig. 2. Serum testosterone concentrations in individual probands, affected sisters, and 
unaffected sisters (6).  
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The most commonly used method for evaluation of the genetic profile in PCOS has been 
the candidate gene approach. Using this approach, severel genes involved in androgen 
synthesis, secretion, metabolism and regulation have been evaluated along with group of 
genes affecting insulin resistance, insulin secretion and inflammation. Candidate genes 
studies however brought only few informations. Genome wide association studies are 
likely to be more informative. Recent sudies therefore applied DNA microarrays to 
evaluate differences in gene expresion in different tissues between PCOS patients and 
controls. Results of these studies may be used to achieve new knowledge of the 
pathogenesis of PCOS which is still unknown. Like other common dissease such 
as diabetes mellitus type 2, PCOS is most likely a multigenetic dissease with several genes 
having small and additive effect.  
Locus on chromosome 19p13 2 appears to be most promissing candidate gene locus. Genes 
involved in the serin phosphorylation of the insulin receptor (INS VNTR, CYP 11), PPAR-
gamma, calpain 10 (CAPN10) and genes coding for sex hormone binding globuline (SHBG), 
androgen receptor and insulin receptor substrate play an important role in the PCOS 
susceptibility (1). PCOS is a heterogenous disease and the genetic profile of different 
fenotypes may differ (5). 
1.6 Environmental factors 
Low birth weight is associated with an icreased risk of insulin resistance and diabetes 
mellitus type 2. Given the association between insulin resistance and hyperandrogenemia 
in patients with PCOS, low birth weight may therefore be associated with an increased 
risk for PCOS. Studies by Prof. Ibanez documented that girls that later developed PCOS 
had significantly lower birth weight than controls (7). However, in population studies low 
birth weight was associated with insulin resistance but not with hyperandrogenemia or 
with adrenal acitivity. These studies support that PCOS is not caused by low birth weight 
alone, but is more likely the result of interaction between genetic and environmental 
factors. There are speculations about influence of androgen exposure to development of 
fetal hyperandrogenic state (8). It is well known that lifestyle can modify PCOS 
phenotype. Environmental factors can be devided into the exogenous i.e. food, vitamin D 
deficiency, exposure to bisphenol A (PBA) – for example in study of Diamanti – Kadarakis 
PCOS women had significantly higher levels of PBA as compared to normal women (9). 
Among endogenous factors the most important are ethnicity, age, glycemia, insulin 
sennsitivity and many others. 
1.7 Hyperinsulinemia and insulin resistance 
The link between PCOS and insulin resistance was first described in 1980 and has later 
been confirmed in many studies. The exact mechanism of insulin resistance in patients 
with metabolic syndrome is however still unknown. Some patients have increased serine 
phosphorylation of beta subunit of insulin receptor but also distant parts of the insulin 
receptor cascade are affected (10). Some authors documented impaired glycogen synthase 
activity which was confirmed by studies on muscle biopsies from patients with PCOS. 
Impaired glucose metabolism in PCOS represents probably primary not secondary 
mechanism. Hyperinsulinaemia is frequently seen in obese PCOS but also in some lean 
PCOS women. Insulin sensitivity has been described to be reduced by 50% in lean PCOS 
patients which was statisticaly significant (11). Insulin stimulates p450c17 activity in 
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ovaries and adrenals leading to increased androgen production. In addition, 
hyperinsulinemia decreases the hepatic SHBG production and through this mechanism 
free testosterone levels increases. Low SHBG is a good predictor of PCOS and is 
associated with impaired insulin sensitivity. The pathogenesis of PCOS may be looked as 
a vicious cycle involving both hyperandrogenaemia and insulin resistance/ 
hyperinsulinemia. Insulin resistance induces hyperinsulinemia and subsequently 
stimulates the ovarian and adrenal hormonal production, inhibits SHBG production and 
testosterone activity increases Figure3 (5).  
 
 
 
 
 
 
 
 
Fig. 3. Hyperinsulinemia and hyperandrogenemia as a vicious cycle in PCOS (5) CV-
cardiovascular, IR insulin resistance, T2M – type 2 diabetes mellitus 
Obesity and body fat distribution have an important influence on insulin sensitivity. 
Although 50% of PCOS women are not obese, obesity could potentially contribute to insulin 
resistance in PCOS. Lean PCOS women seem to have an insulin resistance that intrinsic to 
the syndrome, while in obese PCOS patients obesity additionally contributes to the 
impairment of the glucose metabolism (1). Elucidating the pathogenesis of insulin resistance 
in PCOS will provide insight into an important cause of type 2 diabetes (39). 
Body composition and fat metabolism in PCOS 
Approximately 75% patients with PCOS are overweight, but a high waist-to-hip ratio 
(WHR) indicating increased abdominal fat mass is seen in both normal and overweight 
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patients with PCOS (5). There are only few studies concerning the correlations between 
phenotypic expression, body composition and PCOS, and relationship with the processes of 
growth and sexual maturation and various environmental factors (nutrition, physical 
activity, stress, and other factors). Variation in human body composition and shape ranges 
considerably: many body size and shape indices (height, weight, body composition, and 
proportions) are the result of long evolution process and adaptation to environment. 
Obviously, the morphological body parameters, physiological and biochemical indices are 
complex and compound the interdependent system. If waist circumference and WHR of 
women with PCOS increase, reproductive function and metabolic state of a woman is 
altered more than in cases when there are no changes in these parameters. The 
investigations of the strongest sexual dimorphism sign – the subcutaneous and visceral fat 
topography – showed that women with PCOS have greater adipose tissue mass in the areas 
of the abdomen, waist, and upper arms than control women (12).  
Ghrelin and cholecystokinin secretion following meals are impaired in PCOS, suggesting 
changed appetite regulation. In a study of Glintborg et al. the prevalence of eating disorder 
was 36,3% in women presenting hirsutism, and controversely, PCOS was overrepresented in 
bulimic women (5). The genetic property of subclinical eating behaviour and the link 
between subclinical eating behaviour and PCOS has been studied before but the role of 
leptin within this connection has never been investigated. In the study of Jahanfar et al., 
serum leptin level correlated significantly with bulimia score. The genetic property of 
subclinical eating disorder was not confirmed. Leptin was linked with both subclinical 
eating disorder and PCOS (13).  
In the study of Puder et al., PCOS women had significantly higher trunk to fat ratio (T/E fat) 
as compared with body mass index matched women, they also had higher values of 
inflammatory markers such as highly sensitive C-reactive protein (hsCRP), procalcitonin, 
tumor necrosis factor alpha (TNF-alpha). Additional adjusting to T/E fat eliminated the 
effect of PCOS on insulin resistance and inflammatory markers. They conclude that the 
increase in inflamatory markers in PCOS women is primarly associated with increased 
central fat excess rather than PCOS per se (14). Among other considerations, anomalies of 
plasma growth hormone (GH) secretion and/or altered insulin growth factor I (IGF-I) 
concentrations may play role in the pathogenesis of PCOS. Abdominal obesity, which can 
exacerbate the insulin resistance and reproductive features of the syndrome, is associated 
with profoundly reduced and disorderly GH secretion. A stimulatory role of GH in early 
and later stages of folliculogenesis and ovulation, hyposomatotropism may contribute to 
impaired follicular development and anovulation in PCOS (15). Increased intra-abdominal 
fat is of central importance in PCOS as it affects GH secretion, insulin resistance, lipid 
metabolism, and inflammatory status. Life style modification and weight loss improves 
ovulation rate and fertility and testosterone levels are decreased (5). 
Inflammation 
PCOS is a proinflamatory state as evidenced by elevated plasma concentrations of hsCRP. In 
obesity-related diabetic syndrome, TNF alpha is overexpressed in adipose tissue and 
induces insulin resistance through acute and chronic effects on insulin sensitive tissues. 
Chronic exposure to TNF-alfa decreases the expression of glucose transporter 4 (GLUT4), 
the insulin-sensitive glucose transport protein. Because decreased GLUT4 expression has 
been identified in PCOS, it is possible that TNFalpha contributes to this postreceptor defect. 
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The source of excess circulating TNFalpha in PCOS is likely to be adipose tissue in the 
obese. In lean women with PCOS increased visceral adiposity has been proposed as a source 
of excess TNFalpha (16).  
Systemic review and metaanalysis of relevant studies suggest that adiponectin is lower in 
women with PCOS compared with non-PCOS controls of similar body mass index (BMI). 
Lower adiponectin levels are associated with the insulin resistance observed in women with 
PCOS compared with controls. It has been demonstrated that the more insulin resistant 
women with PCOS recruited, the lower serum adiponectin levels were found (17).  
In PCOS previous studies showed positive associations between leptin and BMI, waist 
circumference and insulin resistance, indicating that fat mass in PCOS is the most important 
predictor of leptin secretion in PCOS and this data do not support a pathogenic role of leptin 
in PCOS. Chemokines such as migration inhibitor factor (MIF), monocyte chomatractant 
protein (MCP-1) and macrophage inflammatory protein (MIP) are increased and in some 
studies and well correlated with testosterone levels in PCOS patients (5, 16). 
Cardiovascular risk factors in PCOS 
High percentage of patients with PCOS have abnormal lipid profiles including increased 
total cholesterol (TC), low densitiy lipoprotein cholesterol (LDL-C), whereas high density 
cholesterol (HDL-C) levels are decreased. Patients with PCOS have increased prevalence 
of coronary atherosclerosis and echocardiography abnormalities but no prospective 
studies exist in PCOS populations. Retrospective studies found significantly increased 
risk of hypertension and cardiovascular disseases and current estimated risk for 
cardiovascular disseases is 4-11 fold increased in PCOS. Patients with PCOS have 5-7 fold 
higher risk for acute myocardial infarction, however no prospective studies exist until this 
time. There is increased CD36 which is expressed on the surface of monocytes and 
macrophages. In addition increased CD36, plasminogene activator inhibitor (PAI-1), 
homocystein were reported to be higher in women with PCOS. Previous studies did not 
found any differences in interleukin 6 (IL-6) between patients with PCOS and controls 
and no effect of metformin or glitazone treatment (1, 5). HsCRP is secreted in response to 
cytokines including IL-6. Despite the fact that data are inconsistent, increased levels of 
hsCRP in patients with PCOS were reported in some previous studies. HsCRP positively 
correlated with DEXA scan whereas no correlation was observed with testosterone levels. 
Pioglitazone-mediated improvement of insulin sensitivity was accompanied by decreased 
hsCRP levels (5, 18). Young women with PCOS mostly have a normal blood pressure, 
while especially older, obese patienst with PCOS suffer from an elevated blood pressure. 
In contrast to adolescent with PCOS who mostly have still normal lipid profiles, women 
with PCOS often have a dyslipidemia (1).  
Risk of type 2 diabetes mellitus  
PCOS is powerful risk factor for impaired glucose tolerance and type 2 diabetes mellitus. 
Insulin-resistant patients with PCOS maintain normal glucose levels by an insulin 
hypersecretion. These patients are at an icreased risk of beta cell exhaustion and 
development of type 2 diabetes mellitus (19). In study of women with PCOS the prevalance 
of diabetes mellitus was up to 7,5% and impaired glucose tolerance was 31% (1,20). 
Metaanalysis of clinical studies has been performed by Moran et al. Totaly 2 192 studies 
were reviewed and 35 were selected for final analysis. Results showed an increased 
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prevalence of impaired glucose tolerance and type 2 diabetes mellitus and metabolic 
syndrome in both BMI and non BMI-matched studies Table 2 (21). 
 
 
OR non BMI BMI-matched 
IGT 2,48 2,58 
DMt2 4,43 4,0 
MS 2,88 2,2 
Table 2. Prevalence of impaired glucose tolerance (IGT) and type 2 diabetes mellitus (DMt2) 
and metabolic syndrome (MS) in BMI and non BMI-matched studies (21) 
Other risks of PCOS 
Among risks related to pregnancy there was documented a higher prevalence of 
gestational diabetes mellitus, which was significantly higher than that in control group of 
women. Moreover, patients with PCOS have significantly higher risk of pregnancy-
induced hypertension, preeclampsia, neonatal complications and higher abortrtion rate. 
Women with PCOS seem to expierence increased risk of cesarean delivery and perinatal 
morbidity and mortality (22). There is also increased risk of breast cancer as well as 
endometrial cancer (33). 
Bone mineral density (BMD) in PCOS 
Several factors may contribute to the conserved BMD in PCOS. Patients with PCOS have 
relatively high levels of estradiol and are characterized by abdominal obesity and insulin 
resistance. Abdominal obesity and increased visceral fat mass are seen in overweight and 
normal-weight patients with PCOS. Adiposity is known to be positively associated with 
BMD. Furthermore, more than 50% of patients with PCOS are insulin resistant, and previous 
studies suggested that hyperinsulinemia, independent of BMI, may protect against the 
development of osteoporosis. Only few studies found positive associations between 
testosterone and BMD in PCOS, but this may in part be explained by the use of imprecise 
testosterone assays in most studies (23). In the study of Glintborg, treatment with 
pioglitazone of insulin-resistant premenopausal patients with PCOS was followed by 
significantly decreased BMD at the hip and lumbar spine and decreased markers of bone 
mineral turnover. These findings suggest that pioglitazone may have adverse effects on 
BMD even in a study population relatively protected from bone mineral loss (23). 
Vitamin D and PCOS 
Recent studies clearly documented that obesity is associated with decreased 25OH vitamin 
D levels. Patients with PCOS and metabolic syndrome had significantly lower levels of 
vitamin D2 being in negative correlation with fasting insulin and insulin sensitivity. 
Supporting the relative vitamin D insuficiency in PCOS some studies found a higher levels 
of parathormone (PTH) in these patients. Association between vitamin D receptor (VDR) 
gene polymorphisms (Apal) and insulin resistance, PTH, 25OH vitamin D is speculated. 
Some authors documented efficacy of vitamin D replacement on insulin resistance and in 
the treatmend of anovulation (24, 25, 26). Low serum 25OH vitamin D concentrations result 
from the presence of obesity and insulin resistance (24).  
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In the study of Wehr et al., the prevalance of vit D deficiency in 206 women affected by 
PCOS was 72.8%. PCOS women with metabolic syndrome had lower vit D levels than PCOS 
women without metabolic symptoms. In multivariate regression analysis 250HD and BMI 
were independent predictors of homeostatic model assessment-insulin resistance index 
(HOMA), vitamin D was also independent predictor of metabolic syndrome in PCOS. There 
was significant positive correlation of vitamin D levels SHBG and quantitative insulin 
sensitivity check index (QUICKI) and a negative one found with BMI, WHR, waist 
circumference, blood pressure, glucose, isnulin, HOMA-IR and triglycerides. Nevertheless 
large intervetion trial are needed to evaluate the effect of vit D supplementation on 
metabolic distubances in PCOS Table 3 (27). 
 
Positive correlation of 25OHD 
SHBG 0,009 
Negative correlations of 25OHD 
Waist circumference 0,001 
Hip circumference 0,001 
Blood pressure 0,05 
Fasting glucose 0,001 
Fasting insulin 0,001 
HOMA IR 0,001 
Triglycerides 0,002 
CRP 0,005 
Table 3. Correlations of vitamin 25OHD (27) 
Autoimmunity and PCOS 
There are some reports regarding the relationship between PCOS and autoimmune 
disorders. However, the data are controversial and some studies documented a higher 
prevalence of antihistone and anti ds-DNA antibodies in PCOS (28). Concerning organ-
specific antibodies, one study clearly demonstrated a high prevalence of antibodies against 
thyroid specific components, higher prevalence of autoimmune thyroiditis and higher 
thyrotropin levels as well (29). There are so far no reports about antiovarian antibodies in 
patients with PCOS. There are speculations about the presence of antivorian simulating 
antibodies analogically to thyroid simulating antibodies (28). As was documented by the 
study of Janssen and colleagues, patients with PCOS had significantly higher frequency of 
antihyroid antibodies and ultrasound picture hypoechogenic thyroid gland (29). 
2. Diagnosis of PCOS 
Diagnostic approach in PCOS includes: 
1. History taking and physical examination  
2. Laboratory and hormonal evaluations 
3. Ovarian ultrasonography 
Physical examination includes: assessment of hirsutism using scoring scale of Feriman and 
Gallwey, measurment of blood pressure, waist and hip ratio. 
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Transvaginal ultrasonography is necessary to confirm polycystic ovaries. 
Laboratory investigations include: total and free testosterone, SHGB, LH, FSH, prolactin, 
17hydroxy-progesterone, dehydroepiandrosterone sulfate (DHEAS), fasting plasma glucose 
and lipids, TSH. 
Secondary evaluation includes exclusion of suspected Cushing syndrome: 24 hours UFC, 
Dexamethasone supression test (overnight, 2 mg 2 days), oral glucose tolerance test if 
fasting blood glucose is between 5,6 - 7,0 mmol/l and magnetic resonance (computer 
tomography) of adrenal glands – if suspected virillizing tumor. 
3. Treatment of PCOS 
Various intervetions have been proposed ranging from life-style modifications, 
administration of pharmaceutical agents (such as clomiphene citrate, insulin sensitizing 
agents, gonadotropins and gonadotropin-releasing hormone analogues), the use of 
laparoscopic ovarian drilling and the application of assisted reproduction techniques (30). 
Treatment is related to the preference of patient and includes: 
1. Treatment of hirsutism or acne 
2. Treatment of oligo/amenorrhea and infertility 
3. Treatment of insulin resistance and metabolic syndrome 
1. Treatment of hirsutism or acne 
Combination of estrogene-progestin therapy in the form of oral contraceptives is the first 
line of endocrine treatment for hirsutism and acne. The estrogenic component is responsible 
for the supression of LH and thus serum androgen levels. It also results in increase of SHBG 
lowering the free fraction of testosterone. Assessment of adequacy of ovarian suppression 
can be made at the end of the third week after starting treatment. The effect on acne can be 
expected to be maximal in 1-2 months. However, the effect on hair growth may not be 
evident for 6 months and the maximum effect requires 9-12 months (31). Cyproterone 
acetate acts by competitive inhibition of the binding of testosterone and dihydrotestosterone 
to the androgen receptors. Spironolactone appears to be as effective an antiandrogen as 
cyproterone actetate in doses 100-200 mg daily. Flutamide is a potent nonsteroidal 
antiandrogen without progestational, estrogenic, corticoid, antigonadotropic effect (32, 33). 
Finasteride is a competitive inhibitor of type 2 5alpha-reductase and for this reason can be 
useful for the treatment of hirsutism (33, 34). 
Gonadotropin-releasing hormone agonists (GnRH agonists) have been reported to be 
effective in the treatment of hirsutism. Their chronic administration supresses pituitary-
ovarian function thus inhibiting both ovarian androgen and estrogen secretion. Addition of 
dexamethasone to leuprolide has been reported to further improve the response in some 
women with PCOS (33). 
Recent randomized, prospecitve trial comparing low dose flutamide, finasteride, ketoconazole 
and combination cyproterone-acetate-ethinyl estradiol demonstrated relative superiority of 
flutamide and cyproterone acetate-ethinyl estradiol in the treatment of hirsutism (33). 
Aims of treatment hirsutism or acne include: 
- suppression of adrenal or ovarian androgen production 
- alteration of binding of androgens to their plasma proteins 
- impairment of the peripheral conversion of androgen precursors to active androgen 
- inhibition of androgen action in peripheral tissues 
www.intechopen.com
 
Polycystic Ovary Syndrome 
 
55 
2. Treatment of oligo/amenorrhea and infertility 
Chronic oligoanovulation results in persistent stimulation of endometrial tissue by estrogen 
increasing the risk of endometrial cancer. A three-fold increased risk of endometrial cancer 
has been reported. Thus anovulatory women with PCOS are recommended to take 
progestins to reduce the risk of endometrial hyperplasia or carcinoma. The combined 
estrogene-progestin therapy is also beneficial in women with PCOS because in both inhibits 
endometrial proliferation and reduces ovarian androgen production (33). In some studies 
insulin sensitizing agents such as metformin and glitazone improved menstrual cycle 
irregularities, however their indication in case when patient does not wish to be pregnant is 
controversial and generally not recommended (30). 
Clomiphene citrate remains still the first line therapy for induction of ovulation in women 
with PCOS. The usual regimen is 50 mg per day for 5 days beginning on cycle day 3 mg 
daily for 5 days, ovulation can be induced in about 80% of women (33). There are many 
reports about combined clomiphene citrate and metformin therapy, unfortunately with 
controversial results. In higher doses metformin together with clomiphene citrate 
significantly improved ovulation rate and pregnancy rate, however did not improved live 
birth rate. Those patients who fail clomiphene therapy will usually require either low dose 
human recombinant FSH or human menoapusal gonadotropin for ovulation induction. 
Pregnancy rate is similar to clomiphene citrate, but live birth rate is lower when compared 
with clomiphene citrate (30, 35, 36). 
There has been renewed interest in surgically inducing ovulation in women with PCOS 
using laparoscopy and electrocautery or laser. Laparoscopic ovarian diathermy (LOD) is 
associated with lower multiple gestation rates than gonadotropins, because LOD can 
achieve unifollicular ovulation. There was no evidence of difference in live birth rate and 
miscarriage in women with clomiphene-resistant PCOS undergoing LOD versus 
gonadotropin treatment. LOD is an alternative to gonadotropin therapy for clomiphene-
citrate resistant anovulatory PCOS. LOD restores menstrual regularity in 63%-85% of 
women, and the benefitial effects on reproductive outcomes seem to last for several years in 
many women (30, 37). 
Progestins: reduce risk of endometrial cancer 
Estrogene-progestin: inhibits endometrial proliferation, reduces androgen production 
Clomiphene citrate: first line therapy (80% ovulation rate) 
Human recombinant FSH: if clomiphene failed 
Human menopausal gonadotropin 
Aromatase inhibitors 
Surgically induced ovulation: laparoscopy, electrocautery, laser (80% pregnancy rate, 80% 
conceptions within first 8 months) 
In vitro fertilization 
3. Treatment of insulin resistance and metabolic syndrome 
Insulin resistance in women with PCOS appears more common than in the general 
population. Many studies show the common coexistence of obesity with insulin resistance, 
particulary in the presence of abdominal phenotype, although this disorder may be present 
even in those with normal weight. PCOS-related insulin resistance is partly independent of 
the presence of obesity, and that obesity in PCOS women simply adds and additional 
deterious effects on insulin sensitivity, by mechanisms that have still not been defined and 
could be different between obese and non-obese PCOS women (38). In women with PCOS, 
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basal insulin secretion is increased and hepatic insulin clearance is reduced, resulting in 
hyperinsulinemia. Obesity and PCOS have a synergistic negative impact on insulin senzitivity. 
In both obese and non-obese PCOS women , insulin secretion is inappropriately low for their 
degree od insulin resistance, suggesting the presence of pancreatic beta-cell dysfunction. There 
is a positive association between insulin and androgen levels in their PCOS subjects (39). 
Insulin resistance also appears to play a pathogenic role in the metabolic syndrome. Metabolic 
syndrome and its components are common in women with PCOS, placing them at increased 
risk for cardiovascular disease (40). Women with PCOS have 11-fold increase in the prevalence 
of metabolic syndrome compared with age-matched controls (41). 
As noted, lowering insulin levels with weight reduction or drugs may induce ovulation in 
obese, hyperinsulinemic women with PCOS. Weight loss prior to improves live birth rate in 
obese women with or without PCOS. Multiple observation studies have noted that weight 
loss is associated with improved spontaneous ovulation rates in women with PCOS, while 
pregnancies have been reported after losing as little as 5% of initial body weight. However 
weight loss is recommended for those who are overweight with a body mass index over 25-
27 kg/m2 (30, 33).  
Insulin resistance is regarded as a major pathophysiological feature of the syndrome. 
Therefore, agents that improve insulin sensitivity, that is, metformin ant thiazolidinediones 
(TZDs), have been extensively trialled in PCOS patients with encouraging results (42).  
Metformin treatment and PCOS 
Metformin is a biguanide agent used in the treatment of type 2 diabetes mellitus. In women 
with PCOS, metformin was sparked by the recognition of its pleiotropic actions on several 
tissues. It lowers serum insulin levels and improves insulin sensitivity not only by its 
glucose lowering effect but also by increasing peripheral glucose utilization. Apart from its 
action on classic insulin-sensitive tissues, it has been clearly demonstrated that metformin 
has a positive effect in the treatment of reproductive abberations in women with PCOS, 
which indirectly suggests a potential direct effect at the ovarian level. Metformin treatment 
increases ovulation rate, improves menstrual cyclicity, and reduces serum androgen levels 
in these patients (38). Metformin appears to affect ovarian function in a dual mode through 
the elevation of insulin excess acting upon the ovary and through direct ovarian effects. 
Regarding the action of metformin on theca cells, data demonstrate reduced CYP17 activity 
in women with PCOS. In rat granulosa cells, metformin treatment was shown to reduce 
basal and FSH-stimulated progesterone and estradiol production (43). Metformin may exert 
a direct effect on granulosa cells through activation of 5´-adenosine monophosphate 
activated protein kinase (AMPK) and subsequent reduction of steroid production (44). 
Stimulation of AMPK appears to be a key mediator of metformin´s action on hepatic 
gluconeogenesis and lipogenesis (43). The analysis of follicular fluid seemed to confirm that 
metformin acts directly on the ovary improving local levels of androgens, ovarian insulin 
resistance and the levels of several growth factors, Figure 4 (52).  
Metformin restores ovulation in a significant proportion of patients with PCOS and has 
resulted in pregnancy. Metformin pretreatment improves the efficacy of clomiphene-citrate 
on PCOS patients with clomiphene-citrate resistance (19, 33). The target dose is 1500-2550 
mg/day. Clinical response is usually seen at the dose of 1000 mg daily (33). Recent small 
studies also suggest that metformin continued during pregnancy reduces the high rates of 
gestational diabetes and first-trimester spontaneous abortion characteristic of PCOS (19, 43). 
Some studies have reported a decrease in TC, LDL-C and triglyceride levels and increase in 
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HDL-C concentration whereas others have not. Another study in its metaanalysis found 
only LDL-C levels to be significantly reduced following metformin treatment, with TC, 
HDL-C a triglyceride remaining unchanged (44). Metformin has been shown to exert 
antiatheroslerotic, anti-inflmatory and antithrombotic properties by reducing carotic intima-
media thickness, endothelin, hsCRP, PAI-1 and leptin and increasing adiponectin levels in 
PCOS patients (42). Metformin treatment has been associated with decreased androgen 
(total and free testosterone, androstendione) and LH levels and increased SHBG and 
DHEAS concentrations (42).  
 
 
Fig. 4. Hypothesis for metformin effects on follicular development (52) 
Knowledge regarding the predictors for metformin response is crucial. Some studies 
demonstrated that metformin appears to benefit to PCOS subjects irrespective of their 
weight or degree of insulin resistance. Metformin may be more effective in insulin-resistance 
PCOS patients with low BMI. There have been examinated genetic factors. Polymorphism of 
serine-threonine kinase gene STK11 was associated with a significantly decreased chance of 
ovulation in PCOS subjects treated with metformin (38). It is commonly expierence that 
obese women, particulary those with morbid obesity, are refractory to metformin therapy. 
Insulin resistant PCOS patients with low BMI were reported to be more likely to respond to 
metformin. However, previous studies did not confirm the predictive value of insulin 
resistance indices for ovulation induction by metformin. Metformin may be able to directly 
affect ovarian steroidogenesis. This drug could affect the central regulation of ovulation by 
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modulating GnRH release through the activation of the hypothalamic AMPK (43). The 
study of Palomba et al. demonstrates that the efficacy of metformin in inducing ovulation 
in patients with polycystic ovary syndrome is probably due to a direct action of the drug 
on the ovary, and that the ovulatory response to the drug seems to be related more to 
local drug sensitivity or resistance than to improvements in the systemic hormonal 
and/or metabolic pattern (52). Treating insulin resistance with metformin may improve 
fertility, facilitate weight loss, improve the lipid profile, reduce the incidence of diabetes, 
and prevent atherosclerosis, myocardial infarction, and stroke (19). It is very difficult to 
conclude regarding the efficacy of metformin in PCOS, since the published data are 
incosistent due to various study designs concerning patients characteristics, weight 
change, dose regimen and outcome meassures. 
TZDs are ligands of the peroxisome proliferator-activator receptor-gamma, a nuclear 
transcription factor. TZDs lower fasting and postprandial glucose levels by increasing 
glucose utilization in skeletal muscle and decreasing hepatic gluconeogenesis and 
ameliorate hypertiglyceridemia (38, 42). In PCOS patients, rosiglitazone treatment 
improved insulin resistance and normalized the menstrual cycle (45). It had beneficial 
effect on serum levels of adipinectin and resistin (46). Rosiglitazone decreased fastig 
glucose and insulin levels, increase HDL-C and reduced TC and LDL-C and triglyceride 
concentration (42). Tarkun et al. observed that rosiglitazone treatment decreased 
androgen production and it had benefecial effects on endothelian dysfunction and low-
grade chronic inflammation in normal weight women with PCOS (47). In another study, 
rosiglitazone therapy decreased androgen levels (DHEAS, total and free testosterone), 
increase SHBG levels, reduced estradiol production and restored menstrual cycles, 
induced ovulation rate and improved hirsutism score (42). Rosiglitazone has been shown 
to enhance both sponateneous and clomiphene-induced ovulation in overweight and 
obese women with PCOS (37,48). However, due to its side effect, it has been withdrawn 
from the market. The efficacy of rosiglitazone and pioglitazone in PCOS has not been 
compared in any study (42). 
Administration of pioglitazone in women with PCOS resulted in remarkable decline in 
fasting serum insulin levels, improvement of insulin sensitivity. Pioglitazone increased 
serum SHBG concentrations, resulting in significant decrease in the free androgen index. 
Treatment was also associated with higher ovulation rates (49). In women with PCOS who 
failed to respond optimally to meformin, when pioglitazone was added, insulin, glucose, 
insulin resistance, insulin secretion, and DHEAS fell, HDL-C, TC and SHBG rose, and 
menstrual regularity improved (50). Application of insulin sensitizers showed favorable 
influence on the basic hormonal deviations in PCOS – the hyperandrogenemia and insulin 
resistance. In cases with PCOS, metformin treatment influences better hyperandrogenemia, 
while rosiglitazone affects more pronouncedly insulin resistance and hyperinsulinemia (51). 
The study of Li et al. included meta-analysis of 10 trials. TZDs were found to be superior to 
metformin in reducing serum levels of free testosterone and DHEAS after 3-month 
treatment. Decreases in triglyceride levels were more pronounced with metformin after 6 
months. Decreases in BMI are greater with metformin treatment as assessed at 3 and 6 
months. The findings do not indicate that metformin is superior to TZDs for the treatment of 
PCOS or vice versa. Between studies, heterogeneity was a major confounder (53). 
TZDs should be used in substitution of or in adition to metformin in insulin-resistant or obese 
PCOS women who do not tolerate or do not respond to metformin therapy. For menstrual 
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disorders, oral contraceptives are considered the primary treatment, with intermittent 
progesterone therapy and insulin-sensitizing agents as alternative therapies (38, 42). 
4. Conclusions 
PCOS is a common disorder which affects 5%-10% of women of reproductive age (1). PCOS 
can be described as a multiorgan disease affecting most endocrine organs including ovaries, 
adrenals, pituitary, fat cells, bones, and endocrine pancreas (5). However, the diagnosis of 
PCOS comprises more than reproductive or cosmetics problems Table 4. PCOS constitutes 
major health issue for young women. Insulin resistance, dyslipidemia and hypertension 
contribute to an enhanced cardiovascular and diabetes risk (1). 
 
Adolescents Reproductive phase Postmenopause 
Oligomenorrhea Infertility Impaired glucose tolerance 
Hirsutism Hirsutism Type 2 diabetes 
Acne Obesity Dyslipidemia 
Obesity Impaired glucose tolerance Hypertension 
  Cardiovaskular risk factors 
Table 4. PCOS throughout the life cycle (1) 
The risk of diabetes is greater in anovulatory women with polycystic ovaries, in obese 
subjects and those with a family history of type 2 diabetes (3). Women with PCOS are at 
significantly increased risk for impaired glucose tolerance and type 2 diabetes (31,1% 
impaired glucose tolerance, 7,5% undiagnosed diabetes) (20, 21). Legro et al. found that not 
only obese but also nonobese PCOS women may also have glucose intolerance (10,3% 
impaired glucose tolerance, 1,5% diabetes) (20). Abdominal obesity appears to be the 
primary determinant of metabolic abnormalities in PCOS (2). Abdominal obesity and 
increased activation of the inflammatory system are seen in both normal weight and obese 
patients with PCOS. (5). Subclinical inflammation and insulin resistance are important 
predictors of cardiovaslular disease. Patients with PCOS have an excess of central fat 
independent of total fat mass. Central fat excess is usually associated with an increase in 
serum inflammatory markers and insulin resistance. On the other hand, sex hormones affect 
body fat distribution and thereby might in part explain the genderspecific differences in 
body fat distribution (14). Insulin resistance and hyperandrogenism may also, either directly 
or indirectly, influence metabolic abnormalities and potentially contribute to abdominal 
obesity (2). Abdominal obesity and insulin resistance stimulate ovarian and adrenal 
androgen production, whereas SHBG levels are decreased (5). Women with PCOS should be 
informed of their long-term risk of type 2 diabetes and likely cardiovascualr disease. There 
is need for a comperhensive screening and education program for women of all ages with 
PCOS (41). While hyperandrogenemia and concomitant hirsutism, acne, or infertility are 
certainly troublesome to a woman, an incereased risk of developing diabetes and 
atherosclerosis has the potential to shorten her lifespan (19).  
PCOS is a unique, natural model for the study of influence of androgen excess on bone mass 
among women. The deleterious effect on bone of amenorrhea is balanced by androgen 
overproduction. Obesity and insulin resistance aggravate hyperandrogenism. Serum 
vitamin D is significantly lower in obese than in non-obese women individuals and may 
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contribute to lower serum 25OH vitamin D in obesity. Hypovitaminosis D results from the 
presence of obesity but is independent of the presence of PCOS. Vitamin D supplementation 
can be useful in the treatment of obese women with PCOS (24). Wehr et al. are the first to 
describe an inverse association of low 25OH vitamin D levels with impaired beta-cell 
function, impaired glucose tolerance, and metabolic syndrome in women with PCOS (27).  
The treatment of infertile women with PCOS is surrounded by many controversies. Before 
any intervention is initiated, the improvement of life-style, especially weigh reduction is 
recomended. Clomiphene-citrate, an anti-estrogen remains the first-line of treatment for 
ovulation induction. Recomended second-line of intervetion is eihter exogenous 
gonadotropins or laparoscopic ovarian surgery. Recomended third-line treatment is in vitro 
fertilization (30). Treating of insulin resistance, when present, with metformin may improve 
fertility, facilitate weight loss, improve the lipid profile, reduce the incidence of diabetes, 
and prevent atherosclerosis, myoacrdial infarction, and stroke (19). The use of metformin 
alone or in combination with life-style modifications has produced a list of metabolic and 
clinical benefits in both obese and non-obese women with PCOS which has allowed an 
indiscriminate use of this compound worldwide (38). On the other hand, according to 
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group metformin use in PCOS 
should be restricted to women with glucose intolerance (30). According to Nestler 
metformin remains an important therapeutic option in the pharmacologic treatment of 
infertility in PCOS, and its use should not be restricted to women with glucose intolerance, 
as recomended by the ESHRE/ASRM Consensus statement (35).  
Because of the high prevalence of PCOS and the long-term implications on metabolic risk 
factors, fertility, and quality of life, doctors need to be aware of the syndrome in daily 
practise (5). In conclusion, it is clear that PCOS is an anigma. Its underlying 
pathophysiology is not fully understood. No treatment is a panacea, because treatments, so 
far, have been directed at the symptoms but not at the syndrome itself (33). 
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